These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 18844286)

  • 1. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders.
    Scuderi C; Filippis DD; Iuvone T; Blasio A; Steardo A; Esposito G
    Phytother Res; 2009 May; 23(5):597-602. PubMed ID: 18844286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phytocannabinoids as novel therapeutic agents in CNS disorders.
    Hill AJ; Williams CM; Whalley BJ; Stephens GJ
    Pharmacol Ther; 2012 Jan; 133(1):79-97. PubMed ID: 21924288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.
    Fasinu PS; Phillips S; ElSohly MA; Walker LA
    Pharmacotherapy; 2016 Jul; 36(7):781-96. PubMed ID: 27285147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications.
    Tambe SM; Mali S; Amin PD; Oliveira M
    J Integr Med; 2023 May; 21(3):236-244. PubMed ID: 36973157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabidiol--recent advances.
    Mechoulam R; Peters M; Murillo-Rodriguez E; Hanus LO
    Chem Biodivers; 2007 Aug; 4(8):1678-92. PubMed ID: 17712814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent.
    Murillo-Rodríguez E; Millán-Aldaco D; Palomero-Rivero M; Mechoulam R; Drucker-Colín R
    Behav Neurosci; 2008 Dec; 122(6):1378-82. PubMed ID: 19045957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved.
    Comelli F; Giagnoni G; Bettoni I; Colleoni M; Costa B
    Phytother Res; 2008 Aug; 22(8):1017-24. PubMed ID: 18618522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurological Aspects of Medical Use of Cannabidiol.
    Mannucci C; Navarra M; Calapai F; Spagnolo EV; Busardò FP; Cas RD; Ippolito FM; Calapai G
    CNS Neurol Disord Drug Targets; 2017; 16(5):541-553. PubMed ID: 28412918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis.
    Giacoppo S; Soundara Rajan T; Galuppo M; Pollastro F; Grassi G; Bramanti P; Mazzon E
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(24):4906-19. PubMed ID: 26744883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
    Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
    Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical use of cannabis. Cannabidiol: a new light for schizophrenia?
    Deiana S
    Drug Test Anal; 2013 Jan; 5(1):46-51. PubMed ID: 23109356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test.
    Moreira FA; Aguiar DC; Guimarães FS
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1466-71. PubMed ID: 16876926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling the Mechanisms of Cannabidiol's Pharmacological Actions: A Comprehensive Research Overview.
    Kalsoom I; Shehzadi K; Li HS; Wen HL; Yu MJ
    Top Curr Chem (Cham); 2024 Jun; 382(2):20. PubMed ID: 38829467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
    Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
    Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabidiol: State of the art and new challenges for therapeutic applications.
    Pisanti S; Malfitano AM; Ciaglia E; Lamberti A; Ranieri R; Cuomo G; Abate M; Faggiana G; Proto MC; Fiore D; Laezza C; Bifulco M
    Pharmacol Ther; 2017 Jul; 175():133-150. PubMed ID: 28232276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats.
    Malone DT; Jongejan D; Taylor DA
    Pharmacol Biochem Behav; 2009 Aug; 93(2):91-6. PubMed ID: 19393686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol.
    Romano B; Borrelli F; Pagano E; Cascio MG; Pertwee RG; Izzo AA
    Phytomedicine; 2014 Apr; 21(5):631-9. PubMed ID: 24373545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol.
    Demirakca T; Sartorius A; Ende G; Meyer N; Welzel H; Skopp G; Mann K; Hermann D
    Drug Alcohol Depend; 2011 Apr; 114(2-3):242-5. PubMed ID: 21050680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of the antipsychotic properties of cannabidiol in humans.
    Iseger TA; Bossong MG
    Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.
    Roser P; Juckel G; Rentzsch J; Nadulski T; Gallinat J; Stadelmann AM
    Eur Neuropsychopharmacol; 2008 Aug; 18(8):569-77. PubMed ID: 18544469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.